🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

MedPlus Health Services Limited MEDPLUS NSEPHARMA

Healthcare · Pharmaceutical Retailers · India
https://www.medplusindia.com
Company Profile ↓
₹676.35
-17.02% 1Y
Mkt Cap₹8,119.90 Cr
P/E36.98
P/B4.26
52W High₹953.90
52W Low₹649.30
Book Value₹164.54
EPS (TTM)₹18.29

Company Overview

MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness items, such as prescription medicines, over-the-counter drugs, vitamins, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 64.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 14.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 37.0, below the sector median of 41.6.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹6,835.33 Cr (+12.3% YoY); net profit ₹219.65 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +12.3%, earnings +46.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.7%, profit CAGR 64.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.71%
1 Year:12.29%

Compounded Profit Growth

5 Years:64.04%
1 Year:46.12%

Stock Price Performance

1 Year:-17.02%
6 Months:-18.57%
3 Months:-21.45%
1 Month:-2.01%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 9% of range
₹649.30 ₹953.90
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)44.68 · Neutral
Price Performance
1M-2.01%
3M-21.45%
6M-18.57%
1Y-17.02%
Valuation vs Sector

P/E of 36.98 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 14.7% over 5 years.
  • Profit CAGR of 64.0% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 29.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
36.98
Industry PE
41.64
Forward P/E
29.82
PEG Ratio
-
Book Value
₹164.54
Price to Book
4.26
P/S
2.33
EV/EBITDA
23.35
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
14.71%
Profit 5Y
64.04%
Revenue (YoY)
12.29%
Earnings (YoY)
46.12%

Profitability & Returns

ROCE
12.20%
ROE
11.12%
ROA
5.59%
Profit Margin
3.21%
Op Margin
5.01%
Gross Margin
25.61%
EPS (Latest Qtr)
₹2.76
EPS (TTM)
₹18.29

Balance Sheet & Liquidity

Debt/Equity
0.72
Quick Ratio
1.00
Current Ratio
3.00
Debt
₹1,424.38 Cr
Total Assets
₹3,932.53 Cr
Current Assets
₹2,068.65 Cr
Working Capital
₹1,379.36 Cr

Ownership

Promoter Holding
30.13%
Chg in Prom Hold
-12.62%
FII / Inst Holding
38.53%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
₹8,119.90 Cr
Total Revenue (TTM)
₹6,835.33 Cr
EBITDA
₹678.69 Cr
Free Cash Flow
₹372.55 Cr
Operating Cash Flow
₹495.58 Cr
Shares Outstanding
₹12.01 Cr
Gross Margin
25.61%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MEDPLUS MedPlus Health Services Limited NSEPHARMA 676.35 36.98 ₹8,119.90 Cr 0.00% 12.20% 11.12% 14.71% 64.04%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 1,253.00 Cr1,284.00 Cr1,409.00 Cr1,441.00 Cr1,490.00 Cr1,489.00 Cr1,576.00 Cr1,561.45 Cr1,509.61 Cr1,542.63 Cr1,679.00 Cr1,806.12 Cr1,864.38 Cr1,879.60 Cr
Cost of Revenue -------1,170.58 Cr1,108.64 Cr1,139.74 Cr-1,333.68 Cr1,370.94 Cr1,419.29 Cr
Gross Profit -------390.86 Cr400.97 Cr402.90 Cr-472.44 Cr493.44 Cr460.31 Cr
Operating Expenses 1,171.00 Cr1,213.00 Cr1,324.00 Cr1,350.00 Cr1,385.00 Cr1,395.00 Cr1,452.00 Cr320.81 Cr328.81 Cr337.79 Cr1,530.00 Cr386.57 Cr400.21 Cr404.99 Cr
Operating Income 26.00 Cr19.00 Cr30.00 Cr35.00 Cr47.00 Cr34.00 Cr61.00 Cr70.06 Cr72.17 Cr65.11 Cr80.00 Cr85.88 Cr93.23 Cr55.32 Cr
EBITDA 82.00 Cr71.00 Cr85.00 Cr92.00 Cr106.00 Cr94.00 Cr124.00 Cr145.04 Cr152.17 Cr145.75 Cr149.00 Cr176.86 Cr189.77 Cr153.07 Cr
Interest Expense 22.00 Cr23.00 Cr24.00 Cr24.00 Cr25.00 Cr25.00 Cr25.00 Cr25.97 Cr26.84 Cr27.36 Cr29.00 Cr30.83 Cr33.48 Cr33.27 Cr
Pretax Income 17.00 Cr5.00 Cr16.00 Cr20.00 Cr32.00 Cr18.00 Cr48.00 Cr56.60 Cr61.12 Cr52.77 Cr69.00 Cr73.29 Cr80.34 Cr41.88 Cr
Tax Provision -9.18 Cr1.30 Cr1.92 Cr6.20 Cr-1.60 Cr3.42 Cr9.12 Cr10.73 Cr9.80 Cr10.42 Cr13.11 Cr15.50 Cr16.37 Cr8.71 Cr
Net Income 27.00 Cr4.00 Cr15.00 Cr14.00 Cr34.00 Cr14.00 Cr39.00 Cr45.89 Cr51.34 Cr42.36 Cr56.00 Cr57.81 Cr63.98 Cr33.18 Cr
Diluted EPS 2.230.321.221.152.791.203.243.824.303.534.634.815.332.76

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,368.00 Cr1,733.00 Cr2,011.00 Cr2,131.00 Cr2,273.00 Cr2,871.00 Cr3,069.00 Cr-4,528.68 Cr5,573.54 Cr6,087.46 Cr6,835.33 Cr
Cost of Revenue --------3,557.69 Cr4,391.63 Cr4,640.66 Cr5,084.61 Cr
Gross Profit --------970.99 Cr1,181.91 Cr1,446.80 Cr1,750.72 Cr
Operating Expenses 1,336.00 Cr1,696.00 Cr1,940.00 Cr2,073.00 Cr2,153.00 Cr2,737.00 Cr2,852.00 Cr-883.66 Cr1,050.38 Cr1,191.92 Cr1,408.05 Cr
Operating Income 23.00 Cr27.00 Cr60.00 Cr46.00 Cr61.00 Cr59.00 Cr129.00 Cr-87.33 Cr131.53 Cr254.88 Cr342.67 Cr
EBITDA 32.00 Cr37.00 Cr71.00 Cr58.00 Cr120.00 Cr134.00 Cr217.00 Cr-312.23 Cr394.09 Cr535.72 Cr678.69 Cr
Interest Expense 14.00 Cr17.00 Cr19.00 Cr28.00 Cr50.00 Cr47.00 Cr55.00 Cr-83.03 Cr96.43 Cr102.59 Cr120.49 Cr
Pretax Income 14.00 Cr19.00 Cr48.00 Cr26.00 Cr23.00 Cr29.00 Cr95.00 Cr-47.16 Cr73.44 Cr183.29 Cr275.33 Cr
Tax Provision 6.44 Cr9.88 Cr19.20 Cr-16.90 Cr11.04 Cr27.26 Cr32.30 Cr--2.94 Cr7.87 Cr33.06 Cr55.72 Cr
Net Income 7.00 Cr9.00 Cr29.00 Cr42.00 Cr12.00 Cr2.00 Cr63.00 Cr-49.76 Cr65.47 Cr150.32 Cr219.65 Cr
Diluted EPS 419.34508.711,620.572,080.06585.46107.021,393.11-4.175.4512.5218.29

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 438.00 Cr509.00 Cr535.00 Cr644.00 Cr959.00 Cr1,349.00 Cr1,566.00 Cr-2,796.72 Cr3,004.80 Cr3,360.09 Cr3,932.53 Cr
Current Assets --------1,480.72 Cr1,567.55 Cr1,843.52 Cr2,068.65 Cr
Cash & Equivalents --------228.38 Cr91.21 Cr86.05 Cr198.41 Cr
Inventory --------1,144.09 Cr1,340.23 Cr1,345.10 Cr1,381.69 Cr
Receivables --------6.68 Cr12.25 Cr7.96 Cr23.04 Cr
Total Liabilities --------1,306.22 Cr1,427.44 Cr1,620.20 Cr1,957.87 Cr
Current Liabilities --------476.58 Cr525.93 Cr576.59 Cr689.29 Cr
Long Term Debt -------0----
Total Debt 170.00 Cr223.00 Cr204.00 Cr162.00 Cr429.00 Cr477.00 Cr590.00 Cr-899.92 Cr1,009.57 Cr1,119.80 Cr1,424.38 Cr
Total Equity 141.17 Cr137.17 Cr148.17 Cr303.19 Cr291.19 Cr528.19 Cr730.45 Cr-1,491.18 Cr1,577.93 Cr1,740.56 Cr1,975.36 Cr
Shares Outstanding --------11.93 Cr11.95 Cr11.97 Cr12.01 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -19.00 Cr-17.00 Cr34.00 Cr32.00 Cr147.00 Cr-7.00 Cr3.00 Cr-90.41 Cr143.74 Cr540.43 Cr495.58 Cr
Investing Cash Flow -16.00 Cr-32.00 Cr-15.00 Cr-18.00 Cr-19.00 Cr-28.00 Cr-35.00 Cr-429.44 Cr-82.80 Cr-317.61 Cr-127.72 Cr
Financing Cash Flow 67.00 Cr35.00 Cr-29.00 Cr-1.00 Cr-83.00 Cr90.00 Cr-6.00 Cr--170.25 Cr-198.10 Cr-227.98 Cr-255.50 Cr
Capital Expenditure -16.00 Cr-18.00 Cr-15.00 Cr0-22.00 Cr-30.00 Cr-54.00 Cr--169.00 Cr-84.40 Cr-59.45 Cr-123.03 Cr
Free Cash Flow -35.00 Cr-35.00 Cr19.00 Cr32.00 Cr125.00 Cr-37.00 Cr-51.00 Cr--78.60 Cr59.34 Cr480.98 Cr372.55 Cr
Net Change in Cash 32.00 Cr-15.00 Cr-10.00 Cr14.00 Cr45.00 Cr56.00 Cr-37.00 Cr-349.60 Cr-137.17 Cr-5.16 Cr112.36 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------21.4%21.2%23.8%25.6%
Operating Margin % 1.7%1.6%3.0%2.2%2.7%2.1%4.2%-1.9%2.4%4.2%5.0%
Net Margin % 0.5%0.5%1.4%2.0%0.5%0.1%2.1%-1.1%1.2%2.5%3.2%
ROE % 5.0%6.6%19.6%13.9%4.1%0.4%8.6%-3.3%4.1%8.6%11.1%
ROCE % --------3.8%5.3%9.2%10.6%

Shareholding Pattern

Insiders
30.13%
Institutions
38.53%
Public Float
55.14%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MEDPLUS

Google News Wed, 22 Jul 2026

Earnings call transcript: MedPlus Health Services Q1 2026 misses EPS, stock falls 10.4% - Investing.com

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQZkIzNkxQS0prbEZXMVFKb3dqSEFpNHd6U3c5QXYyVHk0N0c0dVZQZ1RYMGdaT0FjRFZHenJJZDhkUG5TSGlQaXE2VlZ4TFRtdzQ5d0t0RUdneDFnRHBVek9pZXBXVW5ib2Iyc0x5NUJTaGxCX2JVcjhsalFMZWh0QkdlNEFwdDJTZjNfX3…

Google News Fri, 04 Sep 2026

Medplus Health Services Share: Bull Case vs Bear Case for 2026 - Univest

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOX0dOUlhYUkJndFJfZ3p4bXdHN21wXzNVZHJqTXNyaU9RcWxZLTVSZ25udGhMRVBndVZCS3JLc0pYMVVrdTN5ZTFKeDFMYXR0OUE1VElXRFpwMkxKa0V6Sjhvcm55RTN3TURtblFKUmVuYnlEQjRMVGtqSUZwUklaTUU0NWNJQXUtSlE?oc…

Google News Fri, 04 Sep 2026

Medplus Health Services Ltd. Peer Comparison – Compare with Others - Value Research

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNYnFlRm1Ja25xR1hEc0tyQ2FjOEtYZHJpeFNSaTVHUE9ScGpsV1ZpT2R4OC1kOTBYUjFRX1NoOTZfYXYzdWpwc3ZEMVFLQlhDV1pJU1F2MC1ySXJ5SGpSNG5WVmhHRWhURWljRFdSUGtjSkI1Y1YtNUxkVEREWExWWkVibHM0M18tZ3N3Y1…

Google News Wed, 22 Jul 2026

MedPlus shares tumble 18% after Q1 profit sinks 22%; should you buy? - Business Standard

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOVUROSmRFcUFORkd4WDVYcTZmR3dvbWIxRWFlbzI2cFBnakxwajVvbXFlSHczVHNNYXBBekNYWldmOFJvVU1QOGRBZEg2QmRLX3JpdmZZTFpqNDEycmYxUEI2Q0RGdXZEV0xFLTlfbFNzVWxhOXUtbjhUN2xJTHhiYmRDSUh1bHpId1NfUX…

Google News ue, 30 Jun 2026

Nu-Med Plus to Acquire Avid Gold in Stock Exchange; 4.5M Series A Preferred Issued - TradingView

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQTnVIZldyQmRueWxMSXJlckpzWFd0OGVaYzNrZW1ZRWNfNHNaeHRWVVVWM1BLaTRoMjZVVjgwUG1aREZtY3Y5QWlEUHUwNFNNcUVSamlDYmlDbEtLdUlwOGxMdTMzYk85T29ra2hPOUtKaldfb1hkeXN3X2pYQ3dfWExNZEdTbFlSald5SW…

Google News ue, 01 Sep 2026

MedPlus Health Services Reschedules Board Meeting for Q4FY26 Financial Results Approval - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPekdaM3Y4ZG1qMHBzTUdocFMwWnJfTWt3RmM4ZmJaOERKSHBtYUxKVmpIWmQxV0hYTEhVNUktbV93R1BuNVlCcHp0ekpDVmczZEFacTlRbGdQUjdadHhWZ1RZSUkyVU1EcmtMazZ4clZvWE51b2VUaWJEVGsyOXlmUElud2VLeHlOWmlkZD…

MEDPLUS — Frequently Asked Questions

What is the current share price of MedPlus Health Services Limited (MEDPLUS)?

As of 2026-09-08 04:53 IST, MedPlus Health Services Limited (MEDPLUS) trades at ₹676.35 on NSE. Its 52-week range is ₹649.30 to ₹953.90.

What is the market capitalisation of MEDPLUS?

MedPlus Health Services Limited (MEDPLUS) has a market capitalisation of ₹8,119.90 Cr on NSE.

What is the P/E ratio of MEDPLUS?

MEDPLUS trades at a trailing price-to-earnings (P/E) ratio of 36.98. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 4.26.

What is the return on equity (ROE) of MEDPLUS?

MEDPLUS has a return on equity (ROE) of 11.12%. Its return on capital employed (ROCE) is 12.20%.

Is MEDPLUS a good stock to buy?

This page provides a data-driven analysis of MedPlus Health Services Limited (MEDPLUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space